Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

JTO Clinical and Research Reports(2020)10.1016/j.jtocrr.2020.100105Source: DataRank Database

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations is a research paper published in JTO Clinical and Research Reports (2020). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 2.08)OA: goldTopics (22)IDs (PubMed, PMC, OpenAlex)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Ikei S. Kobayashi,Susumu Kobayashi ORCID,Daniel B. Costa ORCID,Pedro Eduardo Nascimento Silva Vasconcelos ORCID

Live enrichment

PubMed:33728415 PMC:PMC7959160 OpenAlex:https://openalex.org/W3091886622

U.S. Department of Defense

Grant: LC170223

National Cancer Institute

Grant: R01 CA240257

National Cancer Institute

Grant: R37 CA218707

U.S. Department of Defense

National Cancer Institute

FWCI

2.08

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jtocrr.2020.100105

publisherhttps://doi.org/10.1016/j.jtocrr.2020.100105

publisherhttps://api.elsevier.com/content/article/PII:S266636432030151X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S266636432030151X?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/33728415

Fields of Study

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchColorectal Cancer Treatments and Studies

Keywords

Epidermal growth factor receptorOsimertinibExonCancer researchEGFR inhibitorsGefitinibMutantMutationMedicineBiologyErlotinibCancerGeneGeneticsLung cancererbB2C797sEgfr Exon 20 InsertionMobocertinib

Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations

FAIR Checklist

Authors (4)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)